Navigation Links
Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
Date:7/16/2009

PITTSBURGH, July 16 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).

Liothyronine Sodium Tablets are the generic version of King Pharmaceuticals' thyroid deficiency treatment Cytomel(R), which had total U.S. sales of approximately $54 million for the 12 months ending March 31 for the same strengths, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 120 ANDAs pending FDA approval representing $84.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.6 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
2. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
3. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
4. Mylan Announces Successful Matrix Delisting Offer
5. Mylan Announces Change in Board Leadership
6. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
7. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
8. Mylan Declares Quarterly Preferred Stock Dividend
9. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
10. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
11. Mylan Announces Clarinex(R) Settlement Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... eRaiser, recently attended the January ECRM Trade Show in Hilton Head, SC, where it ... international reputation for the quality of its beauty and wellness products. At this trade ...
(Date:1/21/2017)... ... ... is the perfect set of tools for video editors that want to create the illusion ... - CEO of Pixel Film Studios. , Video editors using ProDOF can add realistic ... racking focus from one area into the next. ProDOF comes with 0.5 second, 1.0 ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites ... isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the ... key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Family Dermatology has recently joined their multi-specialty medical group. The dermatology practice ... cosmetic services. , “We’re excited to add this excellent dermatology practice to our ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 ... the freedom of recovery, they often feel shame for having struggled with an eating ... (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
(Date:1/19/2017)... SILVER SPRING, Md. , Jan. 19, 2017 ... for the treatment of Chronic Idiopathic Constipation (CIC) in adult ... patients suffering from chronic gastrointestinal disorders," said Julie Beitz ... in the FDA,s Center for Drug Evaluation and Research. "With ... select the most appropriate treatment for their condition." ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
Breaking Medicine Technology: